Generated by AI
MoonLake Immunotherapeutics Class A Ordinary Shares represent ownership in MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on therapies for inflammatory skin and joint diseases. The company’s lead program is Sonelokimab, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F, and it is being developed across dermatology and rheumatology indications such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. MoonLake’s work centers on advancing targeted immunology treatments for conditions with significant unmet medical needs, positioning the company within the broader biopharmaceutical sector. Its Class A Ordinary Shares provide public-market exposure to a company whose current business is concentrated on clinical development and related biotechnology operations.
WebsiteDorfstrasse 29
Zug, 6300
Switzerland
The latest articles about MLTX.
MoonLake Immunotherapeutics has seen sharp swings over the past few years, and the latest share price level puts fresh focus on a simple question for you as an investor: Is the current valuation of MoonLake Immunotherapeutics stock meaningfully backed up by the strength of its balance sheet and its book value per share? Over the last 3 years the share price has fallen 66.5%, which puts a lot of weight on whether the current market value still lines up with the underlying net assets on the...
MoonLake Immunotherapeutics (MLTX) just posted third quarter 2026 results, reporting a net loss of US$79.55 million and a diluted loss per share of US$0.93. The company also reaffirmed its focus on sonelokimab regulatory milestones. The latest earnings update landed after a sharp pullback, with MoonLake Immunotherapeutics now trading at US$12.56. The 7 day share price return of 7.35% and 30 day gain of 16.08% suggest short term momentum is rebuilding, even though the 90 day share price return...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Jan 8's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Investors talking about MLTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.